Uveitis：市場分析及び予測（～2017）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 12
1.2 List of Figures 15
2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 16
3 Disease Overview 17
3.1 Etiology and Pathophysiology 19
3.1.1 Important Cytokines for the Pathogenesis of Uveitis and Their Role in Emerging Treatments 21
3.1.2 Uveitis and Systemic Diseases 23
3.1.3 Prognosis and Diagnosis 24
3.1.4 Quality of Life 27
3.2 Symptoms 28
4 Epidemiology 29
4.1 Risk Factors and Comorbidities 30
4.1.1 Smoking increases the risk of uveitis and increases its complications 30
4.1.2 Juvenile idiopathic arthritis patients need regular ophthalmologic screenings 31
4.1.3 HLA-positive antigens are linked to certain types of uveitis 32
4.1.4 Uveitis is associated with various autoimmune, neurological, and infectious diseases 32
4.2 Global Trends 34
4.2.1 US 36
4.2.2 5EU 39
4.3 Forecast Methodology 42
4.3.1 Sources Used 45
4.3.2 Sources Not Used 50
4.3.3 Forecast Assumptions and Methods, Incident Cases 51
4.3.4 Forecast Assumptions and Methods, Prevalent Cases 53
4.3.5 Forecast Assumptions and Methods, Etiological and Anatomical Distribution 54
4.3.6 Forecast Assumptions and Methods, Course of the Disease 57
4.3.7 Forecast Assumptions and Methods, Disease Severity 58
4.4 Epidemiological Forecast for Uveitis (2012-2022) 58
4.4.1 Incident Cases of Uveitis 58
4.4.2 Age-Specific Incident Cases of Uveitis 61
4.4.3 Sex-Specific Incident Cases 63
4.4.4 Age-Standardized Incidence Rates 64
4.4.5 Incident Cases by Primary Anatomical Location of Inflammation 65
4.4.6 Incident Cases Segmented by Etiology 66
4.4.7 Incident Cases by Course of Disease 69
4.4.8 Incident Cases by Severity of Disease 71
4.4.9 Prevalent Cases of Uveitis 72
4.4.10 Age-Specific Prevalent Cases of Uveitis 75
4.4.11 Sex-Specific Prevalent Cases of Uveitis 77
4.4.12 Prevalent Cases by Primary Anatomical Location of Inflammation 78
4.4.13 Prevalent Cases by Etiology 79
4.5 Discussion 82
4.5.1 Epidemiological Forecast Insight 82
4.5.2 Limitations of the Analysis 82
4.5.3 Strengths of the Analysis 84
5 Current Treatment Options 85
5.1 Overview 85
5.2 Product Profiles – Major Brands 93
5.2.1 Retisert (Fluocinolone acetonide) 93
5.2.2 Ozurdex (Dexamethasone Acetate) 98
6 Unmet Needs Assessment and Opportunity Analysis 103
6.1 Overview 103
6.2 Unmet Needs Analysis 104
6.2.1 Therapy to maintain vision and control inflammation 104
6.2.2 Drugs with fewer adverse events 106
6.2.3 Increased number of approved and reimbursed treatments 107
6.2.4 Less frequent and more efficient treatment for anterior uveitis patients 108
6.2.5 Development of a non-corticosteroid ocular implant 109
6.2.6 Education of physicians and improved treatment guidelines 109
6.3 Opportunity Analysis 111
6.3.1 A drug that is able to maintain vision 111
6.3.2 A drug with an improved side effect profile 112
7 Research and Development Strategies 113
7.1 Overview 113
7.1.1 Uveitis as an Add-On Indication 113
7.1.2 Uveitis as a First Indication for a New Drug 114
7.1.3 Development of Ophthalmic Routes of Administration 115
7.2 Clinical Trial Design 117
8 Pipeline Assessment 120
8.1 Overview 120
8.2 Promising Drugs in Clinical Development 121
8.2.1 Humira (adalimumab) 121
8.2.2 EGP-437 (dexamethasone acetate) 128
8.2.3 Xoma 052 (gevokizumab) 133
8.2.4 DE-109 (sirolimus) 139
8.2.5 Medidur (fluocinolone acetonide) 144
8.3 Innovative Early-Stage Approaches 151
9 Pipeline Valuation Analysis 154
9.1 Clinical Benchmarks of Key Pipeline Drugs 154
9.2 Commercial Benchmarks of Key Pipeline Drugs 157
9.3 Competitive Assessment 161
9.4 Top-Line Five-Year Forecast 163
9.4.1 US 165
9.4.2 5EU 166
10 Appendix 169
10.1 Bibliography 169
10.2 Abbreviations 181
10.3 Methodology 185
10.4 Forecast Methodology 185
10.4.1 Diagnosed and Treated Uveitis Patients 187
10.4.2 Uveitis: Course of Disease 187
10.4.3 Uveitis: Severity 187
10.4.4 Drugs Included in Each Therapeutic Class 187
10.4.5 Launch and Patent Expiry Dates 188
10.4.6 General Pricing Assumptions 189
10.4.7 Individual Drug Assumptions 189
10.4.8 Generic Erosion 193
10.4.9 Pricing of Pipeline Agents 194
10.5 Physicians and Specialists Included in This Study 195
10.6 About the Authors 196
10.6.1 Author 196
10.6.2 Epidemiologist 197
10.6.3 Global Head of Healthcare 197
10.7 About GlobalData 198
10.8 Disclaimer 198